Viewing nowValsartan 160 mg Tablets
Valsartan 160mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

MFDS item code 200900897 · Notified 2009.01.29 · Insurance code 643305120
Treatment of essential hypertension; reduction of the risk of death after myocardial infarction; treatment of heart failure
This medicine is used to control blood pressure in patients with essential hypertension. It also helps improve heart failure symptoms in patients intolerant to ACE inhibitors, particularly those with NYHA classification II to IV symptoms. In patients with left ventricular failure or decreased contraction function after myocardial infarction, it is used to reduce the risk of death. Thus, it effectively improves cardiovascular health for patients through blood pressure management, heart failure treatment, and reduction of risk after myocardial infarction.
(Tablet) * 40, 80, 160 mg 1. Essential hypertension Take with water during or between meals. It is recommended that the dose be taken at the same time each day (e.g., in the morning), if possible. 1) Adults: Regardless of sex or race, oral administration of 80 mg of valsartan once daily is recommended. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be administered concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years and older): Initiate treatment with 40 mg of this drug once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this drug once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this drug. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this drug once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this drug once daily; do not exceed 80 mg daily. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this drug orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this drug, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this drug twice daily, followed over several weeks by titration, according to the patient's tolerability, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This drug may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required if creatinine clearance is 10 mL/min or higher; however, do not administer this drug to patients with creatinine clearance below 10 mL/min or those on dialysis, as experience with its use in these patients is lacking. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this drug should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Children and adolescents under 18 years of age: Safety and efficacy have not been established. Children and adolescents under 18 years of age: Safety and efficacy have not been established.
This drug can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be stopped immediately if pregnancy is confirmed. Patients with allergic reactions to this drug or severe liver dysfunction or severe renal dysfunction should not use it. Elderly patients, patients with hyperkalemia, and patients with mild to moderate liver dysfunction need to exercise extra caution when taking this drug, as there is a risk of rapid blood pressure drop; starting with a lower dose is advisable. Various side effects such as dizziness, fatigue, headache, and cough may occur while taking this drug; if symptoms are severe, consult a doctor. Patients with heart failure or after myocardial infarction may experience changes in kidney function, so regular kidney function tests are necessary. Due to its blood pressure-lowering effects, this drug may cause syncope upon initial dosing, particularly in patients with low fluid or sodium levels. Because of the risk of hyperkalemia, potassium-sparing diuretics or potassium supplements should be used with caution, and serum potassium levels should be monitored closely. Caution is advised when used with non-steroidal anti-inflammatory drugs (NSAIDs), as the blood pressure-lowering effect may be reduced and kidney function may be affected. Women who are pregnant or planning to become pregnant, as well as nursing mothers, should preferably not take this drug, and if unavoidable, should consult a doctor. Safety for children and adolescents has not been established; therefore, use is not recommended. In case of overdose, there is a risk of hypotension, decreased consciousness, and shock, so immediate medical attention is necessary. This drug should be stored out of the reach of children; transferring it to another container may result in accidents, so caution is necessary.
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a tightly closed container to prevent exposure to air and moisture and in a cool place below 30°C to avoid high temperatures. Doing so will help maintain the drug's effectiveness and prevent degradation.
Grayish orange oval film-coated tablets
98 tablets (14 tablets/PTP × 7)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 160mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.